Ensysce Biosciences Inc. (NASDAQ:ENSC), a clinical-stage company focused on developing innovative solutions for severe pain relief, announced its upcoming Phase 3 clinical trial for PF614, a novel treatment for acute post-surgical pain. The trial will explore the efficacy and safety of Ensysce's Trypsin Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) technologies, designed to provide effective analgesia while reducing the risk of opioid abuse and overdose. The trial results are anticipated to be presented in the future, with the aim of establishing PF614 as a safer opioid option in pain management.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1068649) on September 04, 2025, and is solely responsible for the information contained therein.